170 completed, 22 unknown, 10 recruiting, 8 terminated. 226 Phase 2, 46 Phase 1, 18 Phase 3.
Follow Glaucoma: new trials by email Literature Review of Glaucoma trials Research Report on Glaucoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial) Nicotinamide, Standard Glaucoma Therapy - Glaucoma, Open-angle, Primary Open Angle Glaucoma (POAG) | Phase 2 | Not yet recruiting | University of Chicago | 96 | 2027-06-01 | 2026-10-13 |
| VGFTe-(HD)-OD-2566: Adjunctive Aflibercept Ahmed Glaucoma Valve (AAA) Study Aflibercept Injection, Ahmed Tube Surgery - Glaucoma | Phase 2 | Not yet recruiting | University of Miami | 100 | 2026-12-01 | 2026-10-23 |
| A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure. Arm 1: TB0001 ophthalmic solution 0.9%, Arm 2: TB0001 ophthalmic solution 1.2%, TB0001 ophthalmic solution 1.5% - Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT) | Phase 2 | Recruiting | Tavo Biotherapeutics | 96 | 2026-10-23 | 2026-11-03 |
| A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage ASP2767, Sham ASP2767, Prophylactic Regimen A - Glaucoma | Phase 1 / Phase 2 | Recruiting | Astellas Pharma Global Development, Inc. | 156 | 2026-10-07 | 2026-10-22 |
| Topical Insulin for Glaucoma (TING2) EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month) - Open Angle Glaucoma, Primary Open Angle Glaucoma | Phase 1 / Phase 2 | Enrolling by invitation | Stanford University | 90 | 2026-09-10 | 2026-10-13 |
| REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension REGN22530 - Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT) | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 271 | 2026-09-08 | 2026-09-28 |
| A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy G01 Eye Drops 100μg/ml, G01 Eye Drops 200μg/ml, Placebo of G01 Eye Drops - Primary Open-Angle Glaucoma, Optic Nerve Injury | Phase 2 | Recruiting | Qingdao WanMing BioCell Pharmaceutics Co.,Ltd. | 90 | 2026-03-18 | 2026-08-24 |
| Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension QLS-111-FDC, Latanoprost (0.005%) - OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension | Phase 2 / Phase 3 | Completed | Qlaris Bio, Inc. | 64 | 2026-03-18 | 2026-07-29 |
| Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation QLS-111 Ophthalmic Solution (0.015%), QLS-111 Ophthalmic Solution (0.075%) - Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG) | Phase 2 | Completed | Qlaris Bio, Inc. | 9 | 2026-02-20 | 2026-11-02 |
| GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma GVB-2001-high dose, GVB-2001-low dose - Primary Open-Angle Glaucoma (POAG) | Phase 1 / Phase 2 | Recruiting | IVIEW Therapeutics Inc. | 6 | 2025-11-19 | 2026-05-04 |
| Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension BL1107 Low dose, BL1107 High dose, Timolol maleate 0.5% - Glaucoma | Phase 2 | Completed | Bausch & Lomb Incorporated | 252 | 2025-10-24 | 2026-07-22 |
| Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG) QLS-111 ophthalmic solution (0.015%), Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol) - Normal Tension Glaucoma (NTG), Low-Tension Glaucoma, Bilateral | Phase 2 | Completed | Qlaris Bio, Inc. | 37 | 2025-08-13 | 2026-04-03 |
| Safety and Efficacy of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery TimoD implant, Injector system, Timolol eye drops 0.5% - Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Recruiting | EyeD Pharma | 42 | 2025-06-12 | 2026-07-30 |
| Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure - Glaucoma | Phase 2 | Recruiting | Glaukos Corporation | 110 | 2025-06-12 | 2026-09-17 |
| Metformin as a Neuroprotective Therapy for Glaucoma Metformin, Placebo - Glaucoma | Phase 2 | Recruiting | Christopher Kai Shun Leung | 125 | 2025-06-01 | 2025-11-20 |
| Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension PA5108 Ocular Implant low dose, PA5108 Ocular Implant, high dose, Latanoprost 0.005% Ophthalmic Solution - Glaucoma, Open-Angle, Ocular Hypertension | Phase 2 | Active not recruiting | PolyActiva Pty Ltd | 75 | 2025-05-31 | 2026-07-08 |
| Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients Nicotinamide Riboside, Nicotinamide, Nicotinamide Mononucleotide - Glaucoma | Phase 2 | Recruiting | Christopher Kai Shun Leung | 138 | 2025-05-19 | 2025-06-26 |
| The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK) Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, Placebo - Pseudophakic Bullous Keratopathy, Glaucoma | Phase 2 / Phase 3 | Completed | University Hospital Dubrava | 50 | 2025-05-12 | 2026-09-09 |
| Transdermal Microneedle Lignocaine Delivery Versus EMLA Patch for Topical Analgesia Before Venepuncture Procedure To Adults in Clinical Setting Lignocaine-loaded maltose microneedle array patch, EMLA 5% patch - Glaucoma, Cataract | Phase 1 / Phase 2 | Recruiting | Universiti Kebangsaan Malaysia Medical Centre | 154 | 2025-02-17 | 2025-07-18 |
| Next Generation Rocklatan AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution - Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Alcon Research | 646 | 2024-09-04 | 2026-11-09 |
Showing 20 of 226. Sign in to see all of them.
Ocular Hypertension (143) · Glaucoma, Open-Angle (142) · Low Tension Glaucoma (7) · Glaucoma, Neovascular (6) · Hypertension (6) · Cataract (5) · Eye Diseases (4) · Exfoliation Syndrome (3) · Sturge-Weber Syndrome (3) · Epilepsy (2) · Glaucoma, Angle-Closure (2) · Hydrophthalmos (2) · Macular Degeneration (2) · Optic Nerve Diseases (2)
Eye Diseases (222) · Ocular Hypertension (83) · Cardiovascular Diseases (11) · Vascular Diseases (11) · Nervous System Diseases (8) · Optic Nerve Diseases (8) · Retinal Diseases (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Lens Diseases (4) · Angiomatosis (3) · Brain Diseases (3) · Central Nervous System Diseases (3) · Congenital Abnormalities (3) · Cranial Nerve Diseases (3)
Latanoprost (38) · Ophthalmic Solutions (15) · Bimatoprost (14) · Timolol (14) · Travoprost (9) · Mitomycin (7) · AR-12286 (6) · Brimonidine Tartrate (6) · brinzolamide (6) · netarsudil (6) · anecortave acetate (5) · Bevacizumab (4) · Hanks Balanced Salt Solution (4) · Ranibizumab (4) · dorzolamide (3)
Alcon Research (27) · Aerie Pharmaceuticals (15) · Mati Therapeutics Inc. (11) · Allergan (10) · Qlaris Bio, Inc. (9) · Santen Inc. (9) · Bausch & Lomb Incorporated (6) · ForSight Vision5, Inc. (5) · Glaukos Corporation (5) · Inotek Pharmaceuticals Corporation (3) · Laboratoires Thea (3) · Medical University of Vienna (3) · Santen Pharmaceutical Co., Ltd. (3) · Stanford University (3) · Sylentis, S.A. (3)
United States (150) · Japan (7) · South Korea (6) · Germany (5) · Austria (4) · Singapore (4) · Spain (4) · United Kingdom (4) · Australia (3) · Brazil (3) · Canada (3) · China (3) · Czechia (3) · Israel (3) · Mexico (3)
Michelle Chen, PhD (5) · Oscar Cuzzani, MD (4) · Theresa Landry (4) · Lisa Brandano (3) · Theresa Heah, MD (3) · B. Wirostko, M.D. (2) · Barbara M Wirostko, MD (2) · Carl B Camras, MD (2) · David Wirta, MD (2) · Marlene R Moster, MD (2) · Nancy Ramirez-Davis (2) · Oscar Cuzanni, MD, MSc (2) · Padma Nanduri, MD (2)
PMID 12049574, PMID 10201583, PMID 10664926, PMID 12365904, PMID 12472329, PMID 15885795, PMID 19049301, PMID 19290537, PMID 19850848, PMID 20570237, PMID 21257146, PMID 21794845, PMID 21851167, PMID 2194358, PMID 22207522, PMID 22332206, PMID 22607109, PMID 22835512, PMID 23377586, PMID 24212847, PMID 24248002, PMID 24504128, PMID 24513094, PMID 24794283, PMID 24974815, PMID 25019269, PMID 25826644, PMID 26209587, PMID 27310103, PMID 27312975, PMID 27457257, PMID 27649982, PMID 2806924, PMID 28302155, PMID 28528010, PMID 28957960, PMID 29189540, PMID 29802818, PMID 32533949, PMID 33244711, PMID 33629227, PMID 35076329, PMID 35167779, PMID 35643967, PMID 36055467, PMID 36912740, PMID 38060092, PMID 38536128, PMID 40043909, PMID 40126812
2008 (1), 2009 (1), 2014 (1), 2018 (1)